![conference banner](/images/conference-banner.jpeg)
Abstract
Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Keywords: Cell death, apoptosis, cancer
Current Signal Transduction Therapy
Title: Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Volume: 1 Issue: 1
Author(s): Istvan Petak, Janet A. Houghton and Laszlo Kopper
Affiliation:
Keywords: Cell death, apoptosis, cancer
Abstract: Suppression of cell death (most often apoptosis) by survival signals, or by defects in cell death signal transduction pathways, is considered one of the obligate hallmarks of malignant transformation. However, molecular survival strategies to evade cell death only have relevance in the presence of pro-death signals. Discovery of the apoptotic properties of oncogenes responsible for increased tumor cell proliferation (e.g. c-Myc) provided the most important example for such signals and led to the concept of synthetic lethal targeting as a strategy of identifying cancer specific drug target molecules. Besides growth signal autonomy, other hallmarks of oncogenesis (insensitivity to anti-growth signals, limitless replicative potential, invasion and metastasis, angiogenesis and increased genomic instability) are also challenged by increased susceptibility to various forms of cell death. Therefore, cancer cells must acquire survival strategies to suppress these cell death/apoptosis mechanisms. Novel signal transduction therapies can target molecules involved in these strategies to trigger tumor specific cell death.
Export Options
About this article
Cite this article as:
Petak Istvan, Houghton A. Janet and Kopper Laszlo, Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269217
DOI https://dx.doi.org/10.2174/157436206775269217 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Substrate-dependent Inhibition of Hypericin on Human Carboxylesterase 2: Implications
for Herb-drug Combination
Current Drug Metabolism Benzamide Riboside, a Recent Inhibitor of Inosine 5-Monophosphate Dehydrogenase Induces Transferrin Receptors in Cancer Cells
Current Medicinal Chemistry Phytochemical-based Nanoformulations for Drug-resistant Brain Cancer
Nanoscience & Nanotechnology-Asia Synthesis of Prenylated Xanthones: An Overview
Current Organic Chemistry Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Nanogel-based Transdermal Drug Delivery System: A Therapeutic Strategy with Under Discussed Potential
Current Topics in Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Fighting Carcinogenesis with Plant Metabolites by Weakening Proliferative Signaling and Disabling Replicative Immortality Networks of Rapidly Dividing and Invading Cancerous Cells
Current Drug Delivery Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Extracorporeal Shock Wave Therapy in Inflammatory Diseases: Molecular Mechanism that Triggers Anti-Inflammatory Action
Current Medicinal Chemistry Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety